Cancer discovery news

A new drug is having a dramatic effect on shrinking lung cancer tumours, according to new research.

Giving patients with suspected bladder cancer an MRI scan before surgery could mean they would be treated more quickly, leading to fewer deaths due to the disease, new ICR-led research suggests.

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, experts are urging.

Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research.

Scientists have identified a more accurate way of predicting which patients with multiple myeloma, a type of blood cancer, are likely to relapse early following treatment.

Suffering from psychological stress could further increase cancer risk in those already genetically predisposed to the disease, according to new research.

A new study has revealed a promising therapeutic strategy for pancreatic cancer, offering new hope for people living with this disease.

Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to new findings from a nationwide clinical trial.

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer.

Scientists have developed a new test that can decode when someone’s cancer first started growing and how fast it is growing, potentially allowing doctors to accurately predict when a patient will need treatment.

Two studies have uncovered how combining a cancer-killing reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies.

Whole-body MRI scans provide powerful insights into treatment effectiveness and long-term outcomes for patients with myeloma, an incurable but treatable blood cancer.  Results from the iTIMM study led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London have shown that whole-body MRI scans (WB-MRI) can detect tiny traces of the disease, known as minimal residual disease (MRD), in the bone marrow after treatment. This can provide a crucial insight into how well patients with multiple myeloma are responding to treatment and whether they might relapse - offering a potential new standard in how this complex blood cancer is assessed.